We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Expands Leading Health Practice with Addition of Christine Bloomquist

04 June 2012

WASHINGTON, D.C., 4 June 2012 – Hogan Lovells announced today that Christine E. Bloomquist joined its Health practice in Washington, D.C. as a partner. Bloomquist will focus her practice on advising pharmaceutical and medical device companies on fraud and abuse compliance and pricing issues as well as on other regulatory and policy matters, including aspects of the Affordable Care Act.

“Christie’s significant experience, skill set, and reputation within the industry will further enhance our ability to offer health regulatory compliance and fraud and abuse counseling to our pharmaceutical and medical device clients,” said Liz Dunst, partner with Hogan Lovells’ Health practice.

“Christie brings a unique combination of pharmaceutical industry insights from her extensive career in private practice and her years spent in-house focusing on government relations,” said Tom Bulleit, partner with Hogan Lovells’ Health practice.

Prior to joining Hogan Lovells, Bloomquist served as Senior Director, Federal Government Affairs, with AstraZeneca Pharmaceuticals LP in Washington, D.C. In this role, she was the chief healthcare lobbyist for AstraZeneca and represented the company’s interests during the passage and implementation of the Affordable Care Act and during deficit reduction negotiations last summer. Bloomquist worked closely with commercial business leaders and industry senior executives throughout her tenure at AstraZeneca. In her previous roles in private practice, she advised pharmaceutical and medical device manufacturers and entities in the delivery supply chain on a vast array of fraud and abuse (principally Anti-Kickback and Stark), compliance, and reimbursement issues.

Bloomquist also has advised manufacturers on the full range of compliance and policy issues, including bundled discounts, grants, and sales and marketing activities. Additionally, she has provided guidance on drug pricing issues (Medicaid rebate program and Part B pricing calculations) and assisted clients in preparing annual reports required under Corporate Integrity Agreements.

“With its world-class reputation as a leader in the field of health law and its highly regarded team, Hogan Lovells is the ideal platform from which I can develop my practice and advise clients on a wide range of fraud and abuse, policy and regulatory matters,” said Bloomquist.

 
Loading data